


ACCURUN® 30

EBV IgG Positive Control



LGC Clinical Diagnostics, Inc. | 37 Birch Street, Milford, MA 01757 USA
Phone: +1 508.244.6400 | CDx-Info@LGCGroup.com

MEDIMARK® Europe
11, rue Émile Zola BP 2332
38033 Grenoble Cedex 2 – France
+ 33 (0) 4 76 86 43 22
info@medimark-europe.com

10081US-09 September 2021

Explanation of symbols used in LGC Clinical Diagnostics product labeling



Upper limit of temperature



Temperature limitation



Authorized Representative in
the European Community



Biological risks



Use By



In Vitro Diagnostic Medical Device



Negative control



Catalogue number



Consult instructions for use



Positive control



Batch code



Manufacturer



Control



Highly Flammable



Toxic by inhalation, in contact
with skin and if swallowed



Health Hazard



ACCURUN® 30 EBV IgG Positive Control

NAME AND INTENDED USE

ACCURUN controls are intended to estimate laboratory testing precision and can be used to detect errors in laboratory testing procedures. ACCURUN® 30 EBV IgG Positive Control is formulated for use with *in vitro* diagnostic test kits for the detection of IgG antibodies to Epstein-Barr Viral Capsid Antigen (VCA) and Epstein-Barr Nuclear Antigen (EBNA). *For In Vitro Diagnostic Use*.

SUMMARY

Frequent testing of independent quality control samples provides the analyst with a means of monitoring the performance of laboratory assays. Routine use of controls enables laboratories to monitor day-to-day test variation, lot-to-lot performance of test kits, and operator variation, and can assist in identifying increases in random or systematic error. A well-designed quality control program can provide added confidence in the reliability of results obtained for unknown specimens. The use of low-reactive samples as independent controls may provide valuable information concerning laboratory proficiency and kit lot variation that may affect assay sensitivity¹.

PRINCIPLES OF THE PROCEDURE

ACCURUN 30 EBV IgG Positive Control is designed for use with *in vitro* assay procedures for purposes of monitoring test performance. ACCURUN 30 EBV IgG Positive Control is manufactured from human serum or plasma reactive for IgG antibodies to EBV VCA and EBNA, and nonreactive for HBsAg and antibodies to HIV 1 and 2, HTLV, and HCV. ACCURUN controls do not have assigned values. Specific levels of reactivity will vary among different manufacturers' assays, different procedures, different lot numbers, and different laboratories.

REAGENTS

Item No. 2000-0037 3 vials, 1.0 mL per vial

This control contains stabilizers (EDTA and buffering agents), and 0.1% ProClin® (5-chloro-2-methyl-4-isothiazolin-3-one & 2-methyl-4-isothiazolin-3-one) as preservative.

WARNINGS AND PRECAUTIONS

For In Vitro Diagnostic Use.

CAUTION: Handle ACCURUN controls and all human blood products as though capable of transmitting infectious agents. ACCURUN 30 EBV IgG Positive Control is manufactured from human serum or plasma nonreactive for HBsAg and antibodies to HIV 1 and 2, HTLV, and HCV with current FDA licensed tests.

Safety Precautions

Use the Centers for Disease Control (CDC) recommended universal precautions for handling ACCURUN and human blood². Do not pipette by mouth; do not eat or drink in areas where specimens are being handled. Clean any spillage by immediately wiping up with 0.5% sodium hypochlorite solution. Dispose of all specimens, controls and materials used in testing as though they contain infectious agents.

Handling Precautions

Do not use ACCURUN controls beyond the expiration date. Avoid microbial contamination of the controls when opening and closing the vials.

STORAGE INSTRUCTIONS

Store ACCURUN 30 EBV IgG Positive Control frozen at -20°C. Once opened, ACCURUN 30 EBV IgG Positive Control should be stored at 2-8°C and discarded after 60 days. After opening, record the date opened and the expiration date on the vial. Multiple freeze-thaw cycles are not recommended, and may have variable adverse effects upon test results. To prevent leakage, store vials upright.

INDICATIONS OF REAGENT INSTABILITY OR DETERIORATION

Alterations in physical appearance may indicate instability or deterioration of ACCURUN controls. Solutions that are visibly turbid should be discarded.

PROCEDURE

Materials Provided

ACCURUN 30 EBV IgG Positive Control is manufactured from human serum or plasma reactive for EBV VCA IgG and EBNA IgG and nonreactive for HBsAg and antibodies to HIV 1 and 2, HTLV, and HCV.

Materials Required but not Provided

Refer to instructions supplied by manufacturers of the test kits to be used.

Instructions for Use

Allow the controls to reach room temperature prior to use, then return controls to refrigerated storage immediately after use. Mix the contents of the vials by gentle inversion. ACCURUN controls should be included in a test run using exactly the same procedure provided by the manufacturer for unknown specimens. ACCURUN controls must NOT be substituted for the positive and negative control reagents provided with manufactured test kits.

Quality Control

Since ACCURUN controls do not have assigned values, it is recommended that each laboratory validate the use of each lot of ACCURUN with each specific assay system prior to its routine use in the laboratory.

INTERPRETATION OF RESULTS

Levels of reactivity of ACCURUN 30 EBV IgG Positive Control may vary with different manufacturers' tests and different test kit lots. Since the control does not have an assigned value, the laboratory must establish a range for each lot of ACCURUN 30 EBV IgG Positive Control. When results for ACCURUN 30 EBV IgG Positive Control are outside the established acceptable range of values, it may be an indication of unsatisfactory test performance. Possible sources of discrepancy include: deterioration of test kit reagents, operator error, faulty performance of equipment, or contamination of reagents.

LIMITATIONS OF THE PROCEDURE

ACCURUN CONTROLS MUST NOT BE SUBSTITUTED FOR THE POSITIVE AND NEGATIVE CONTROL REAGENTS PROVIDED WITH MANUFACTURED TEST KITS.

TEST PROCEDURES and *INTERPRETATION OF RESULTS* provided by manufacturers of test kits must be followed closely. Deviations from procedures recommended by test kit manufacturers may produce unreliable results. ACCURUN controls are not calibrators and should not be used for assay calibration. Performance characteristics for ACCURUN 30 EBV IgG Positive Control have been established only for EBV VCA IgG and EBNA IgG. Adverse shipping and/or storage conditions or use of outdated controls may produce erroneous results.

EXPECTED RESULTS

ACCURUN 30 EBV IgG Positive Control DOES NOT HAVE AN ASSIGNED VALUE. Specific levels of reactivity will vary among different manufacturers' assays, different procedures, different lot numbers, and different laboratories. Procedures for implementing a quality assurance program and monitoring test performance on a routine basis must be established by each individual laboratory. Each laboratory should establish its own range of acceptable values for each analyte. For example, the acceptable range might include all values within 2 standard deviations of the mean of 20 data points obtained in 20 runs over a period of 30 days³.

SPECIFIC PERFORMANCE CHARACTERISTICS

ACCURUN controls are designed for use with *in vitro* assay procedures for purposes of monitoring assay performance. ACCURUN 30 EBV IgG Positive Control is manufactured from human serum or plasma reactive for EBV VCA IgG and EBNA IgG antibodies and nonreactive for HBsAg and antibodies to HIV 1 and 2, HTLV, and HCV. ACCURUN controls do not have assigned values. Specific levels of reactivity will vary among different manufacturers' assays, different procedures, different lot numbers, and different laboratories. Procedures for implementing a quality assurance program and monitoring test performance on a routine basis must be established by each individual laboratory.

REFERENCES

- Green IV GA, Carey RN, Westgard JO, Carten T, Shablesky LA, Achord D, Page E, and Le AV. Quality control for qualitative assays: quantitative QC procedure designed to assure analytical quality required for an ELISA for hepatitis B surface antigen. *Clin. Chem.* 43:9 1618-1621, 1997.
- Siegel JD, Rhinehart E, Jackson M, Chiarello L, and the Healthcare Infection Control Practices Advisory Committee, 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings.
- Statistical Quality Control for Quantitative Measurements: Principles and Definitions; Approved Guideline—Second Edition. NCCLS document C24-A2, 1999.

For assistance, contact LGC Clinical Diagnostics Technical Support at +1.508.244.6400.